Malignant neoplasm of corpus uteri, unspecified
ICD-10 C54.9 is a billable code used to indicate a diagnosis of malignant neoplasm of corpus uteri, unspecified.
C54.9 refers to a malignant neoplasm located in the corpus uteri, which is the main body of the uterus. This code is used when the specific type of malignancy is not specified, making it essential for coders to ensure that all relevant clinical information is documented. The corpus uteri is a common site for gynecologic cancers, including endometrial carcinoma, which is the most prevalent type of uterine cancer. Symptoms may include abnormal vaginal bleeding, pelvic pain, and changes in menstrual patterns. Diagnosis typically involves imaging studies, biopsy, and histopathological examination. Staging of the cancer is crucial for treatment planning and prognosis, often utilizing the FIGO (International Federation of Gynecology and Obstetrics) staging system. CA-125, a tumor marker, may be elevated in cases of endometrial cancer, aiding in diagnosis and monitoring treatment response. Surgical approaches may include hysterectomy, which is the primary treatment for localized disease, and may be accompanied by lymphadenectomy to assess for metastasis. Understanding the nuances of this code is vital for accurate billing and treatment planning.
Detailed documentation of symptoms, imaging results, biopsy findings, and treatment plans.
Diagnosis of endometrial cancer, staging assessments, and treatment planning.
Ensure clarity in documentation regarding the type of malignancy and staging to avoid coding errors.
Comprehensive records of treatment regimens, response to therapy, and follow-up care.
Management of patients undergoing chemotherapy or radiation therapy for uterine cancer.
Accurate documentation of tumor markers like CA-125 and their relevance to treatment outcomes.
Used for treatment of malignant neoplasm of the uterus.
Operative report detailing the procedure and findings.
Gynecologic oncologists should ensure comprehensive documentation of the malignancy type.
Document all relevant clinical findings, including symptoms, imaging results, biopsy reports, and treatment plans. Ensure clarity regarding the unspecified nature of the malignancy.
